Recent WHO data suggests that 1 in 8 people in the world are living with obesity

The FDA recently granted approval to Lifileucel as the first one-time cell therapy and the first tumor-infiltrating lymphocytes (TIL) therapy for a solid tumor, melanoma, which is an advanced skin cancer. TIL technology has taken nearly four decades to reach maturity. TIL therapy is a type of treatment in which tumor-infiltrating lymphocytes (a type of immune cell that can recognize and kill cancer cells) are removed from a patient’s tumor and grown in large numbers in a laboratory.

55 Novel therapeutics were approved by the U.S. FDA’s Center for Drug Evaluation & Research in 2023, the second highest in the past 30 years.